Sanofi (SNY) Common Equity (2009 - 2025)

Sanofi has disclosed Common Equity across 13 years of filings, most recently posting $83.1 billion for Q4 2025.

• Common Equity for Q4 2025 came in at $83.1 billion, changed 0.32% year-over-year; the trailing twelve-month figure through Dec 2025 was $83.1 billion (changed 0.32% YoY), and the FY2025 annual result was $83.1 billion, changed 0.32% from the prior year.
• Common Equity came in at $83.1 billion for Q4 2025 at Sanofi, roughly flat from $82.8 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $83.1 billion in Q4 2025 to a low of $76.3 billion in Q4 2022.
• The 5-year median for Common Equity is $79.7 billion (2023), against an average of $80.1 billion.
• Across the five-year window, Common Equity rose 4.42% in 2021 and slipped 2.89% in 2022, its largest moves.
• Sanofi's Common Equity stood at $78.6 billion in 2021, then decreased by 2.89% to $76.3 billion in 2022, then grew by 4.41% to $79.7 billion in 2023, then increased by 3.97% to $82.8 billion in 2024, then increased by 0.32% to $83.1 billion in 2025.
• The last three Common Equity figures came in at $83.1 billion (Q4 2025), $82.8 billion (Q4 2024), and $79.7 billion (Q4 2023), per Business Quant data.